trending Market Intelligence /marketintelligence/en/news-insights/trending/ih2ignhsslf2eck8b7hj3g2 content esgSubNav
In This List

VolitionRx closes $8.4M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


VolitionRx closes $8.4M common stock offering

Life sciences company VolitionRx Ltd. closed an underwritten public offering of 3.5 million common shares at $2.40 apiece to raise gross proceeds of about $8.4 million.

The net proceeds will be used for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes.

Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering, while National Securities Corp. acted as a co-manager for the offering.